GCP
DNTH icon

GSA Capital Partners’s Dianthus Therapeutics DNTH Stock Holding History

GSA Capital Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,715
Closed -$400K – 1820
2025
Q4 		$400K Buy
+9,715
New +$377K 0.03% 966
2022
Q2 		– Sell
-2,666
Closed -$124K – 1481
2022
Q1 		$124K Buy
2,666
+870
+48% +$47.5K 0.02% 1262
2021
Q4 		$127K Buy
+1,796
New +$181K 0.02% 1293

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GSA Capital Partners's DNTH Position: Q1 2026 in Review

GSA Capital Partners sold out of Dianthus Therapeutics (DNTH) in Q1 2026, closing a stake of 9,715 shares — an estimated $400K sold.

GSA Capital Partners first reported a position in DNTH in Q4 2021 and held it in 3 quarters. The position peaked at $400K in Q4 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • GSA Capital Partners reported no remaining Dianthus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 9,715 Dianthus Therapeutics shares in Q1 2026, an estimated $400K.
  • GSA Capital Partners first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 3 quarters.
  • GSA Capital Partners's Dianthus Therapeutics position peaked at $400K in Q4 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.